Instem (INS)

 

INS Share PerformanceMore

52 week high328.55 26/09/16
52 week low182.00 28/03/17
52 week change -15.00 (-7.23%)
4 week volume382,905 03/03/17

Media for (INS)

Presenter: Phil Reason, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Instem revenues up 12%

Instem's revenues increased 12% to 18.3m in the year to the end of December with recurring revenues up 21% at 12.1m and ...

Final Results

RNS Number: 6813A Instem plc 28 March 2017 This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Instem plc ("Instem", the "Company" or the "Group") Unaudited Full Year Results Instem (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, announces its unaudited...

Investor Teach-in

RNS Number: 9033Y Instem plc 09 March 2017 Instem plc ("Instem") Investor Teach-in Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces it will be holding a teach-in for investors and analysts on Tuesday, 28th March 2017. The event will be held in the Black Bar, upstairs at Rocket Bar, 6 Adams Cou...

Notice of Results

RNS Number: 6280Y Instem plc 07 March 2017 Instem plc Notice of Results Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, will announce full year results for the year ended 31 December 2016 on Tuesday 28 March 2017. Management will be hosting a presentation for analysts on the day of the results at 9.30...

Instem revenues up 11%

Instem, a leading provider of IT solutions to the global early development healthcare market, says revenues for the year en...

Instem revenues up

Trading Statement

RNS Number: 1888U Instem plc 16 January 2017 16 January 2017 Instem plc ("Instem" or the "Company") Period End Trading Update Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces a period end trading update for the year ended 31 December 2016. Revenues for the year increased by approximat...

Instem appoints COO

Instem, a leading provider of IT solutions to the global early development healthcare market, has appointed MaryBeth Tho...

Fundamental DataMore

EPS-3.5
Dividend yield0 %

Equity Research (INS)

progressive research
Instem plc
16/01/2017
Instem has published a short trading update for the year to December 2016. The outcome was in line with (and in some areas slightly ahead of) our expectations. The year was impacted by the slowdown...
progressive research
Instem plc
21/12/2016
Instem recently confirmed that its Instem Clinical business continues to be impacted by a slowdown in the early-phase clinical market and, despite other areas of Instem performing well, that this...
progressive research
Instem plc
19/09/2016
Instem has announced solid interim results. Revenues grew by 21% YoY, accompanied by a 34% improvement in EBITDA. Activity in the pre-clinical segment remains strong, as evidenced by the multi-year...

Latest discussion posts More

  • NEW ARTICLE: Instem worth 24% more

    "I first spoke to LSE:INS:Instem early last year. The AIM-listed company was worth A#22 million and demand for its software, which helps drug companies develop commercial drugs ...
    19-Sep-2016
    II Editor

Users' HoldingsMore

Users who hold Instem also hold..
AMEC FOSTER30%
VECTURA30%
ANGLE30%
BT GROUP30%
RDS 'B'30%

Codes & Symbols

ISINGB00B3TQCK30
SymbolsINS, LSE:INS, INS.L, INS:LN, LON:INS, XLON:INS